Devoted to research

Navigating through metabolic disorders at the subcellular level, our research aims to understand organelles at the core of the pathogenesis, develop novel biomarkers and uncover potential drug targets.

  1. Research Projects

Research projects

CENTOGENE embraces the vision of patient engagement in healthcare decisions, as we move further into the era of personalized medicine.

Together with renowned international scientists and academic institutions, e.g. Universities of Rostock, Lübeck, Greifswald, we conduct several epidemiological studies with global partners.

These joint projects involve hundreds of patients affected with disorders such as Fabry, Pompe, Krabbe, various forms of mucopolysacharoidoses and others. International collaborations yield a rich collection of genetic and biochemical data which are used to map out phenotype-genotype correlations and improve the accuracy of diagnostics and prognostics.


  • BioGM1/BioGM2

    The goal of this study is to validate this new biochemical marker from the plasma of affected patients helping to benefit other patients by an early diagnosis and thereby with earlier treatment.

  • BioHurler

    The goal of this study is to identify and validate a new biochemical marker from the plasma of affected patients helping to benefit other patients by an early diagnosis and thereby with earlier treatment.

  • BioFarber

    Farber disease, also known as Farber’s lipogranulomatosis, is an autosomal recessive lysosomal storage disease marked by a deficiency in enzyme ceramidase which causes a progressive accumulation of fatty material lipids leading to abnormalities in the joints, liver, throat, tissues, and central…

  • BioKrabbe

    The goal of this study is to develop new biochemical markers from the plasma of affected patients, helping to benefit the patient with early diagnosis and thereby with earlier treatment.

  • BioGaucher

    The goal of the study is to validate this new biochemical marker from the plasma of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.

  • BioHunt

    The validation of this new biochemical marker from the plasma and saliva of the affected patients is the goal of this study.

  • BioNPC

    We estimate, that every 300th newborn in some countries may be eligible for inclusion due to high-grade suspicion of NPC. The validation of this new biochemical marker from the plasma and saliva of the affected patients is the goal of this study.

  • Pancreatitis cancer research project

    It is still hardly possible to predict the genetic risk of developing pancreatic cancer whereas it is common for e.g. breast cancer. With the support of the Ministry of Economics Mecklenburg-West Pomerania and the European Union, Greifswald and Rostock scientists work intensively to develop a…


CentoAcademy® Master Course Series at CENTOGENE

Don’t miss the chance to participate in CENTOGENE´s CME accredited Master Course Series 2017.

Show Upcoming Workshops

CentoWebinar

Register for our next webinar "NGS and beyond: Pioneering the new genome-based panel generation"

Register now